QUOTE AND NEWS
SeekingAlpha  Jul 25  Comment 
CR Bard (NYSE:BCR) Q2 2014 Earnings Call July 24, 2014 5:00 pm ET Executives Timothy M. Ring - Chairman, Chief Executive Officer and Chairman of Executive Committee John H. Weiland - President, Chief Operating Officer and Director ...
newratings.com  Jul 24  Comment 
WASHINGTON (dpa-AFX) - C. R. Bard Inc. (BCR) Thursday reported second-quarter net loss of $119.4 million or $1.59 per share, compared to net loss of $161.6 million or $2.03 per share last year. Adjusted earnings for the quarter were $2.06 per...
Forbes  Jul 23  Comment 
Wall Street is optimistic about C.R. Bard, which is slated to report its second quarter results on Thursday, July 24, 2014. Analysts project a profit of $2.00 a share, a rise from $1.42 per share a year ago.The consensus estimate remains unchanged...
Market Intelligence Center  Jul 2  Comment 
Tuesday’s trading in Bard (C.R.) Inc (BCR) gives options traders an opportunity for a 29.20% return. By selling the Oct. '14 $150.00 call and buying the Jan. '15 call at the $125.00 level for a net debit of $19.35, traders will book a profit as...
Benzinga  Jun 20  Comment 
In a report published Friday, S&P Capital analyst Jeffrey Loo downgraded the rating on C.R. Bard (NYSE: BCR) from Buy to Hold, but raised the price target from $145.00 to $150.00. In the report, S&P Capital noted, “We raise our target price $5...
Benzinga  Jun 18  Comment 
Shares of C.R. Bard (NYSE: BCR) are down following a report from Barclays regarding test results and the Medtronic (NYSE: MDT) and Covidien (NYSE: COV) merger, which may “create a headwind.” Analyst Matthew Taylor writes about...
TheStreet.com  Jun 18  Comment 
NEW YORK (TheStreet) -- Barclays downgraded C.R. Bard  to "equal weight" from "overweight." The firm noted pressure on the company due to its exposure to the peripheral vascular space affected by the Medtronic  deal with Covidien .  The...
TheStreet.com  Jun 18  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Ambit Biosciences was initiated with a sell rating at TheStreet Ratings. Gap was upgraded at Canaccord Genuity to buy from hold. Twelve-month price target is $51. Company can continue to expand margins,...
Benzinga  Jun 18  Comment 
Analysts at BMO Capital downgraded Covidien plc (NYSE: COV) from “outperform” to “market perform.” The target price for Covidien has been raised from $78.00 to $93.22. Covidien's shares closed at $88.12 yesterday. JP Morgan downgraded...
Benzinga  Jun 13  Comment 
In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Underweight rating and $127.00 price target on C.R. Bard (NYSE: BCR). In the report, Morgan Stanley noted, “The panel unanimously voted Bard's DCB approvable, a...




 
TOP CONTRIBUTORS

C.R. Bard (NYSE: BCR) manufactures medical devices such as stents and catheters. The company leads in market share in nearly all its markets.

Oncology was one of Bard's fastest growing therapeutic areas, with over 19% sales growth. Cancer is the second leading cause of death in developed countries and the third worldwide, and people spend billions of dollars annually on cancer research and treatment.

Business Overview

Business Segments

BCR breaks its operations into four segments: i) Vascular, ii) Urology, iii) Oncology, and iv) Surgical Specialties.

Urology Products (27% of 2009 Revenues)[1]

Bard’s leading urology product is the foley catheter, which Bard introduced in 1934. Other urology products include urine monitoring and collection systems, surgical slings (used to treat urinary incontinence), and other devices.

Vascular Products (28% of 2009 Revenues)[1]

Bard makes a wide range of products for the vascular market, including catheters, stents, accessories, and others.

Oncology Products (27% of 2009 Revenues)[1]

Bard’s oncology products cover a wide range of devices used in the treatment and management of various cancers, including specialty catheters, ultrasound devices, and feeding devices. [2]

Surgical Specialty Products (15% of 2009 Revenues)[1]

Bard’s surgical specialty products such as meshes and irrigation devices are primarily used for groin hernia repairs - Bard is the leader in this market segment.

Business Financials

BCR’s revenues are diversified across four operating divisions. BCR doesn’t have huge blockbuster products which contribute a significant amount of revenue, but rather a big diversified portfolio of products.

BCR has had steady growth over the past four years from 2006 to 2009. In 2009, total revenues were $2.53 billion, a modest increase from its previous year's revenues of $2.45 billion.[3] As a result of this increase in total revenues, BCR's 2009 net income rose to $460 million compared to $417 million for the previous year.[3]

Key Trends and Forces

Medicare coverage patterns impacts reimbursement

Health coverage is an important determining factor when patients and doctors choose among various treatment options. Medicare coverage is particularly significant in that it directly affects over forty million Americans, how much patients have to pay for Bard products, and how much Bard will receive in payments from Medicare. Currently, Medicare and other third party payors are emphasizing more cost-effective products and services, by limiting the reimbursement they will cover. Furthermore, even if a new medical or surgical device is cleared by the FDA, Bard faces limited demand for the device until Medicare and other payors approves it for reimbursement. Both of these factors can affect Bard's sales. Bard's products tend to be less controversial and significantly less expensive than some of its competitors, Medtronic's pace makers for instance, and therefore may be less affected by continuing governmental pressure to cut Medicare costs.

Increasing incidence of cancer drives double digit growth in Bard's oncology division

In the U.S. and other developed countries, cancer is responsible for around 25% of all deaths, second only to cardiovascular disease. The most common methods of treatment of Cancer are surgery, radiation therapy, and chemotherapy (drug therapy), which are often used in conjunction with one another to treat various aspects of cancer. Bard has a wide range of products which are used to treat and manage various aspects of cancer. If the incidence of cancer continues, this could continue to drive sales for the company's Oncology division.

Government regulation affects product launches

Bard and its competitors are all heavily affected by government regulation, especially by the FDA, which is responsible for regulating food, dietary supplements, drugs, medical devices, and other products in the United States. Without FDA approval, Bard cannot sell any of its medical products to the public. If any of Bard's products fail FDA approval, it can adversely affect the company's sales.

Competition

BCR faces formidable competition in all of its business divisions:

References

  1. 1.0 1.1 1.2 1.3 BCR 10-K 2009 Item 1 Pg. I-1
  2. BCR 2006 10k, I-3
  3. 3.0 3.1 BCR 10-K 2009 Item 6 Pg. II-2
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki